Edwards Lifesciences Corp (NYSE:EW) – Analysts at Leerink Swann decreased their FY2018 earnings per share estimates for Edwards Lifesciences in a research report issued on Wednesday, January 16th. Leerink Swann analyst D. Antalffy now forecasts that the medical research company will post earnings per share of $4.70 for the year, down from their prior forecast of $4.71. Leerink Swann also issued estimates for Edwards Lifesciences’ FY2020 earnings at $5.75 EPS.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The company had revenue of $906.60 million during the quarter, compared to the consensus estimate of $927.56 million. During the same quarter last year, the firm earned $0.84 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis.

A number of other analysts have also recently issued reports on the company. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Friday. Canaccord Genuity raised their target price on Edwards Lifesciences from $177.00 to $186.00 and gave the company a “positive” rating in a research note on Wednesday. Deutsche Bank began coverage on Edwards Lifesciences in a report on Wednesday, January 2nd. They issued a “hold” rating and a $164.00 target price for the company. Citigroup lifted their price objective on Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a report on Wednesday, January 2nd. Finally, Credit Suisse Group started coverage on Edwards Lifesciences in a report on Monday, December 17th. They set an “outperform” rating and a $188.00 price target for the company. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $165.81.

Shares of EW opened at $159.11 on Friday. The company has a market capitalization of $32.75 billion, a price-to-earnings ratio of 41.87, a price-to-earnings-growth ratio of 1.85 and a beta of 0.90. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. Edwards Lifesciences has a 52-week low of $119.93 and a 52-week high of $175.00.

A number of hedge funds have recently bought and sold shares of EW. FMR LLC raised its stake in shares of Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after acquiring an additional 1,663,511 shares during the period. Paloma Partners Management Co lifted its stake in Edwards Lifesciences by 218.3% in the second quarter. Paloma Partners Management Co now owns 5,450 shares of the medical research company’s stock valued at $794,000 after acquiring an additional 3,738 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $2,007,000. Centaurus Financial Inc. acquired a new position in Edwards Lifesciences during the 2nd quarter valued at $114,000. Finally, Putnam Investments LLC increased its holdings in Edwards Lifesciences by 7.4% in the 2nd quarter. Putnam Investments LLC now owns 68,479 shares of the medical research company’s stock valued at $9,969,000 after buying an additional 4,723 shares during the period. Institutional investors own 82.31% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Friday, December 21st. The stock was sold at an average price of $146.03, for a total transaction of $4,789,784.00. Following the transaction, the chief executive officer now owns 75,926 shares of the company’s stock, valued at $11,087,473.78. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Monday, October 29th. The stock was sold at an average price of $140.74, for a total value of $4,630,346.00. The disclosure for this sale can be found here. Insiders have sold a total of 221,272 shares of company stock worth $32,781,593 over the last quarter. Corporate insiders own 1.84% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: Reverse Stock Split

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.